APA (7th ed.) Citation

Eiermann, W., Pienkowski, T., Crown, J., Sadeghi, S., Chan, A., Saleh, M., . . . Mackey, J. (2011). Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. American Society of Clinical Oncology.

Chicago Style (17th ed.) Citation

Eiermann, W., et al. Phase III Study of Doxorubicin/cyclophosphamide with Concomitant Versus Sequential Docetaxel as Adjuvant Treatment in Patients with Human Epiderman Growth Factor Receptor 2-normal, Node-positive Breast Cancer: BCIRG-005 Trial. American Society of Clinical Oncology, 2011.

MLA (9th ed.) Citation

Eiermann, W., et al. Phase III Study of Doxorubicin/cyclophosphamide with Concomitant Versus Sequential Docetaxel as Adjuvant Treatment in Patients with Human Epiderman Growth Factor Receptor 2-normal, Node-positive Breast Cancer: BCIRG-005 Trial. American Society of Clinical Oncology, 2011.